The SAKK Young Oncology Academy is taking place for the seventh time this year. 10 young oncologists are participating in this year's program. Last week's presentation course in Bern, given by Peter de Boer, is the first course of the year-long program.
#SAKK #CancerResearch
The SAKK Patient Advisory Board is relieved that the ban on animal and human testing was rejected by the people and the cantons at the weekend. This means that swiss patients will still have access to the medical progress in oncology.
#SAKK #Cancer #CancerResearch
Hans Rudolf Keller is the new CEO of SAKK
The Board of the Swiss Group for Clinical Cancer Research (SAKK) has elected Hans Ru- dolf Keller as its new CEO. The 57-year-old from Bern succeeds Martin Reist, who is to leave SAKK.
The 2nd SMASH started! Join us in order to talk about the latest news from the ASH Annual Congress!
oncoviews.com/sakk/
#SAKK #OncoViews #ASH #hematology
SAKK Young Oncology Academy 2021
preparing for the speech at the highlight of the year session at #SOHC2021
#SAKK #YoungOncologyAcademy #Oncology #hematology
Enrolling patients in SAKK 11/16 Phase II #ClinicalTrial Head and Neck Squamous Cell Carcinoma (#HNSCC) Switzerland. Using #personalised #immunotherapy in advanced HNSCC, composed of irradiated tumour cells from #patients and #immunebooster #GM-CSF.
Info: [email protected]
